BRAVELLE - urofollitropin
Ferring Pharmaceuticals Inc.
Bravelle® is a product containing a highly purified preparation of human follicle stimulating hormone (hFSH) extracted from the urine of postmenopausal women. Human FSH consists of two non-covalently linked glycoproteins designated as the α and β subunits. The α subunit has 92 amino acids of which two are modified by attachment of carbohydrates. The β subunit has 111 amino acids of which two are modified by attachment of carbohydrates.
Bravelle® is a sterile, lyophilized powder intended for subcutaneous (SC) or intramuscular (IM) injection after reconstitution with sterile 0.9% Sodium Chloride Injection, USP. Each vial of Bravelle® contains 82.5 International Units (IU) of Follicle Stimulating Hormone (FSH) activity, 23 mg Lactose Monohydrate, 0.005 mg Polysorbate 20, and Sodium Phosphate buffer (Sodium Phosphate dibasic, Heptahydrate and Phosphoric acid) for pH adjustments, which, when reconstituted with diluent, will deliver 75 IU of FSH. Bravelle® contains up to 2% luteinizing hormone (LH) activity based on bioassay. Human Chorionic Gonadotropin (hCG) is not detected in Bravelle®. When stored at 3° to 25°C, up to 40% of the α-subunits may be oxidized.
The in vivo biological activity of urofollitropin for injection, purified is determined by using reference standards calibrated against the First International Standard for follicle- stimulating hormone, (FSH, Urofollitropin), Urinary, Human for Bioassay, National Institute for Biological Standards and Control (NIBSC) at its 46th meeting in 1995.
FSH is a glycoprotein that is acidic and water-soluble. Therapeutic class: Infertility.
Therapeutic class: Infertility.
Bravelle® administered for 7 to 12 days produces ovarian follicular growth in women who do not have primary ovarian failure. Treatment with Bravelle® in most instances results only in follicular growth and maturation. When sufficient follicular maturation has occurred, hCG must be given to induce ovulation.
Single doses of 225 IU and multiple daily doses (7 days) of 150 IU of Bravelle® were administered to healthy volunteer female subjects while their endogenous FSH was suppressed. Sixteen subjects received Bravelle® SC and 12 received the drug IM. Serum FSH concentrations were determined. Based on the steady state ratio of FSH Cmax and AUC, SC and IM administration of Bravelle® were not bioequivalent. Multiple doses of Bravelle® IM resulted in Cmax and AUC of 77.7% and 81.8% compared to multiple doses of Bravelle® SC. The FSH pharmacokinetic parameters for single and multiple dose Bravelle®, administered SC and IM are in Table 1.
|Single Dose (225 IU)||Multiple Dose X 7 (150 IU)|
|Cmax (mIU/mL)||6.0 (1.7)||8.8 (4.5)||14.8 (2.9)||11.5 (2.9)|
|Tmax (hrs)||20. (7.7)||17.4 (12.2)||9.6 (2.1)||11.3 (8.4)|
|379 (111)||331 (179)||234.7 (77.0)||192.1 (52.3)|
|Ka (hr -1)||0.0500 (0.0231)||0.1408 (0.1227)||0.0905 (0.0383)||0.0358 (0.0108)|
The maximum plasma concentration of FSH was attained at 20.5 and 17.4 hours following SC and IM single dose administration, respectively. However, following multiple dosing, it was attained at approximately 10 hours following both routes of administration.
The mean elimination half-lives of FSH for SC and IM single dosing are 31.8 and 37 hours, respectively. However, following multiple dosing (X 7 days) they are 20.6 and 15.2 hours for SC and IM, respectively.
The safety and efficacy of Bravelle® in renal and hepatic insufficiency have not been studied.
The efficacy of Bravelle® was established in two randomized, active controlled, multi-center studies, one for in-vitro fertilization [IVF] and one for ovulation induction [0I].
In the randomized, controlled ovulation induction study, patients underwent pituitary suppression with a GnRH agonist before being randomized to Bravelle® SC, Bravelle® IM or a commercial recombinant FSH product administered SC. A total of 111 oligo-anovulatory patients were randomized of whom 72: received Bravelle®, starting at a dose of 150 IU daily for 5 days. This was followed by individual titration of the dose from 75 to 450 IU daily Based on ultrasound and estradiol (E2) levels. The total duration of dosing did not exceed 12 days. Results for the Intent-To-Treat Population are summarized in Table 2.
|Ovulation (%)||24 (68.6)||26 (70.3)|
|Received hCG (%)||25 (71.4)||28 (75.7)|
|Mean Peak Serum E2 (pg/mL) (SD)||976.5 (680.6)||893.2 (815.2)|
|Chemical Pregnancy (%)||11 (31.4)||8 (21.6)|
|Clinical Pregnancy (%)||9 (25.7)||7 (18.9)|
|Continuing Pregnancy (%)||9 (25.7)||7 (18.9)|
|Pts. w/Live Births (%)||9 (25.7)||6 (16.2)|
In the randomized, controlled IVF study FPI FSH 2001-01, patients underwent pituitary suppression with a GnRH agonist before being randomized to Bravelle® SC or a commercial recombinant FSH product administered SC. A total of 120 patients were randomized of whom 60 received Bravelle®, starting at a dose of 225 IU daily for 5 days. This was followed by individual titration of the dose from 75 to 450 IU daily based on ultrasound and estradiol (E2) levels. The total duration of dosing did not exceed 12 days. Results are summarized in Table 3 for the Intent-To-Treat population.
|Mean Total Oocytes Retrieved Per Patient (SD)||11.8 (6.3)|
|Mean Mature Oocytes Retrieved Per Patient (SD)||9.0 (5.7)|
|Patients with Oocyte Retrieval (%)||57 (95.0)|
|Patients with Embryo Transfer (%)||57 (95.0)|
|Patients with Chemical Pregnancy (%)||28 (46.6)|
|Patients with Clinical Pregnancy (%)||25 (41.7)|
|Patients with Continuing Pregnancy (%)||23 (38.3)|
Bravelle® administered SC or IM in conjunction with hCG, is indicated for ovulation induction in patients who have previously received pituitary suppression.
Bravelle® administered SC in conjunction with hCG is indicated for multiple follicular development (controlled ovarian stimulation) during ART cycles in patients who have previously received pituitary suppression.
Bravelle® is contraindicated in women who have:
Bravelle® is a drug that should only be used by physicians who are thoroughly familiar with infertility problems. It is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome [OHSS] with or without pulmonary or vascular complications in women. Bravelle® therapy requires a certain time commitment by physicians and supportive health professionals, and its use requires the availability of appropriate monitoring facilities (see PRECAUTIONS - Laboratory Tests). Bravelle® should be used with a great deal of care.
Ovarian Enlargement: Mild to moderate uncomplicated ovarian enlargement which may be accompanied by abdominal distension and/or abdominal pain occurs in approximately 20% of those treated with follitropin and hCG, and generally regresses without treatment within two or three weeks.
In order to minimize the hazard associated with the occasional abnormal ovarian enlargement, which may occur with FSH - hCG therapy, the lowest dose consistent with expectation of good results should be used. Careful monitoring of ovarian response can further minimize the risk of overstimulation.
If the ovaries are abnormally enlarged on the last day of Bravelle® therapy, hCG should not be administered in the course of therapy; this will reduce the chances of development of the Ovarian Hyperstimulation Syndrome.
OHSS: OHSS is a medical event distinct from uncomplicated ovarian enlargement. OHSS may progress rapidly to become a serious medical event. It is characterized by an apparent dramatic increase in vascular permeability, which can result in a rapid accumulation of fluid in the peritoneal cavity, thorax, and potentially, the pericardium. The early warning signs of development of OHSS are severe pelvic pain, nausea, vomiting, and weight gain. The following symptomatology has been seen with cases of OHSS: abdominal pain, abdominal distension, gastrointestinal symptoms including nausea, vomiting and diarrhea, severe ovarian enlargement, weight gain, dyspnea, and oliguria. Clinical evaluation may reveal hypovolemia, hemoconcentration, electrolyte imbalances, ascites, hemoperitoneum, pleural effusions, hydrothorax, acute pulmonary distress, and thromboembolic events (see "Pulmonary and Vascular Complications" below). Transient liver function test abnormalities suggestive of hepatic dysfunction, which may be accompanied by morphologic changes on liver biopsy, have been reported in association with the Ovarian Hyperstimulation Syndrome (OHSS).
In a clinical study of ovulation induction, 6 of 72 (8.33%) Bravelle® treated women developed OHSS and two were classified as severe. In a clinical study for multiple follicular development during IVF, 3 of 60 Bravelle® treated women developed OHSS and 1 was classified as severe. Cases of OHSS are more common, more severe and more protracted if pregnancy occurs. OHSS develops rapidly; therefore patients should be followed for at least two weeks after hCG administration. Most often, OHSS occurs after treatment has been discontinued and reaches its maximum at about 7 to 10 days after treatment. Usually, in cases where OHSS may be developing prior to hCG administration (see PRECAUTIONS - Laboratory Tests), the hCG should be withheld.
If severe OHSS occurs, treatment must be stopped and the patient should be hospitalized.
A physician experienced in the management of the syndrome, or who is experienced in the management of fluid and electrolyte imbalances should be consulted.
Serious pulmonary conditions (e.g. atelectasis, acute respiratory distress syndrome) have been reported. In addition, thromboembolic events both in association with, and separate from, the Ovarian Hyperstimulation Syndrome have been reported following FSH therapy. Intravascular thrombosis and embolism, which may originate in venous or arterial vessels, can result in reduced blood flow to critical organs or the extremities. Sequelae of such events have included venous thrombophlebitis, pulmonary embolism, pulmonary infarction, cerebral vascular occlusion (stroke), and arterial occlusion resulting in loss of limb. In rare cases, pulmonary complications and/or thromboembolic events have resulted in death.
Multiple pregnancies have occurred following treatment with Bravelle® SC and IM.
Pregnancy outcomes in a controlled study of 72 patients undergoing ovulation induction with Bravelle® are shown in Table 4.
|Bravelle® SC||Bravelle® IM|
|Total Continuing Pregnancies||9(100)||7(100)|
|Total No. with Multiple Pregnancies||6(66.7)||2(28.6)|
The pregnancy outcomes in a controlled study of 60 patients undergoing treatment with Bravelle® in IVF are shown in Table 5.
|Total No. of Continuing Pregnancies||23(100)|
|Total No. of Multiple Pregnancies||8 (34.8)|
The patient and her partner should be advised of the potential risk of multiple births before starting treatment.
Hypersensitivity/anaphylactic reactions associated with urofollitropins for injection, purifi ed administration have been reported in some patients. These reactions presented as generalized urticaria, facial edema, angioneurotic edema, and/or dyspnea suggestive of laryngeal edema. The relationship of these symptoms to uncharacterized urinary proteins is uncertain.
Careful attention should be given to the diagnosis of infertility in the selection of candidates for Bravelle® therapy (see "INDICATIONS AND USAGE - Selection of Patients")
Prior to therapy with Bravelle® patients should be informed of the duration of treatment and the monitoring of their condition that will be required. Possible adverse reactions (see ADVERSE REACTIONS section) and the risk of multiple births should also be discussed.
The combination of both estradiol levels and ultrasonography are useful for monitoring the growth and development of follicles, timing hCG administration, as well as minimizing the risk of the Ovarian Hyperstimulation Syndrome and multiple gestations.
The clinical confirmation of ovulation, is determined by:
a. A rise in basal body temperature,
b. Increase in serum progesterone, and
c. Menstruation following the shift in basal body temperature.
When used in conjunction with indices of progesterone production, sonographic visualization of the ovaries will assist in determining if ovulation has occurred. Sonographic evidence of ovulation may include the following:
a. Fluid in the cul-de-sac,
b. Ovarian stigmata, and
c. Collapsed follicle.
Because of the subjectivity of the various tests for the determination of follicular maturation and ovulation, it cannot be overemphasized that the physician should choose tests with which he/she is thoroughly familiar.
Long-term toxicity studies in animals and in vitro mutagenicity tests have not been performed to evaluate the carcinogenic potential of urofollitropin for injection, purified.
Pregnancy Category X: See CONTRAINDICATIONS section.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in the nursing infant from Bravelle®, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
The safety of Bravelle® was examined in four clinical studies that enrolled a total of 222 patients receiving Bravelle® including 72 for ovulation induction and 150 for IVF.
All adverse events (without regard to causality assessment) occurring ≥2% incidence in the clinical study patients receiving Bravelle® are listed in Table 6, (FPI FSH 99-03 study for ovulation induction) and Table 7 (FPI FSH 99-04, FPI FSH 99-05 and FPI FSH 2001-01 studies for IVF).
|All Patients with Adverse Events ≥ 2%|
|Adverse Events(%)||Bravelle® SC||Bravelle® IM|
|OHSS||4 (11.4)||2 (5.4)|
|Vaginal Hemorrhage||3 (8.6)||0 (0.0)|
|Ovarian Disorder (Pain, Cyst)||1 (2.9)||3 (8.1)|
|Urinary tract infection||0||1 (2.7)|
|Cervix disorder||1 (2.9)||0|
|Nausea||2 (5.7)||0 (0.0)|
|Enlarged Abdomen||1 (2.9)||1 (2.7)|
|Abdominal Pain||1 (2.9)||2 (5.4)|
|Weight gain||1 (2.9)||0|
|Exfoliative dermatitis||0||1 (2.7)|
|Other Body Systems|
|Headache||4 (11.4)||3 (8.1)|
|Pain||2 (5.7)||0 (0.0)|
|Neck pain||0||1 (2.7)|
|Respiratory Disorder||2 (5.7)||0 (0.0)|
|Hot Flashes||2 (5.7)||0 (0.0)|
|Emotional lability||0||1 (2.7)|
|Accidental injury||0||1 (2.7)|
|All Patients with Adverse Events ≥ 2%|
|Adverse Events (%)||Bravelle® SC
|Vaginal hemorrhage||7 (4.7)|
|Post retrieval pain||12 (8.0)|
|Pelvic pain/cramps||10 (6.7)|
|Uterine spasms||4 (2.7)|
|Vaginal spotting||4 (2.7)|
|Urinary tract infection||5 (3.3)|
|Ovarian disorder||3 (2.0)|
|Breast tenderness||3 (2.0)|
|Vaginal Discharge||4 (2.7)|
|Infection fungal||3 (2.0)|
|Abdominal cramps||21 (14.0)|
|Abdominal pain||7 (4.7)|
|Abdominal fullness/enlargement||10 (6.7)|
|Other Body Systems|
|Respiratory disorder||6 (4.0)|
|Injection site reaction||6 (4.0)|
|Hot flash||6 (4.0)|
|Emotional lability||3 (2.0)|
The following medical events have been reported subsequent to pregnancies resulting from gonadotropin therapy in published clinical studies:
The following adverse reactions have been previously reported during urofollitropin for injection, purified therapy:
The dose of Bravelle® to stimulate development of ovarian follicles must be individualized for each patient. The lowest dose consistent with achieving good results based on clinical experience and reported clinical data should be used.
The recommended initial dose of Bravelle® for patients who have received GnRH agonist or antagonist pituitary suppression is 150 IU daily administered SC or IM for the first 5 days of treatment. Based on clinical monitoring (including serum estradiol levels and vaginal ultrasound results) subsequent dosing should be adjusted according to individual patient response. Adjustments in dose should not be made more frequently than once every 2 days and should not exceed more than 75 to 150 IU per adjustment. The maximum daily dose of Bravelle® should not exceed 450 IU and in most cases dosing beyond 12 days is not recommended.
If patient response to Bravelle® is appropriate, hCG (5000 to 10,000 USP units) should be given 1 day following the last dose of Bravelle®. The hCG should be withheld if the serum estradiol is greater than 2000 pg/mL, if the ovaries are abnormally enlarged or if abdominal pain occurs, and the patient should be advised to refrain from intercourse. These precautions may reduce the risk of Ovarian Hyperstimulation Syndrome and multiple gestations. Patients should be followed closely for at least 2 weeks after hCG administration. If there is inadequate follicle development or ovulation without subsequent pregnancy, the course of treatment with Bravelle® may be repeated. The couple should be encouraged to have intercourse daily, beginning on the day prior to the administration of hCG until ovulation becomes apparent from the indices employed for the determination of progestational, activity. In the light of the foregoing indices and parameters mentioned, it should become obvious that, unless a physician is willing to devote considerable time to these patients and be familiar with and conduct the necessary laboratory studies, he/she should not use Bravelle®.
The recommended initial dose of Bravelle® for patients undergoing IVF and donor egg patients who have received GnRH agonist or antagonist pituitary suppression is 225 IU daily administered SC for the first 5 days of treatment. Based on clinical monitoring (including serum estradiol levels and vaginal ultrasound results) subsequent dosing should be adjusted according to individual patient response. Adjustments in dose should not be made more frequently than once every 2 days and should not exceed more than 75 to 150 IU per adjustment. The maximum daily dose of Bravelle® given should not exceed 450 IU and in most cases dosing beyond 12 days is not recommended.
Once adequate follicular development is evident, hCG (5,000-10,000 USP units) should be administered to induce final follicular maturation in preparation for oocyte retrieval. The administration of hCG must be withheld in cases where the ovaries are abnormally enlarged on the last day of therapy. This should reduce the chance of developing OHSS.
Bravelle® (urofollitropin for injection, purified) is supplied in a sterile, lyophilized, single dose vial containing 82.5 IU of FSH, to deliver 75 IU FSH after reconstituting with the diluent.
Each vial is available with an accompanying vial of sterile diluent containing 2 mL of 0.9% Sodium Chloride Injection, USP.
75 IU FSH activity, supplied as:
NDC 55566-8505-2: Box of 5 vials + 5 vials diluent.
NDC 55566-8505-6: Box of 5 vials + 5 vials diluent + 5 Q●Cap™ vial adaptors.
Lyophilized powder may be stored refrigerated or at room temperature (3° to 25° C/37° to 77°F). Protect from light. Use immediately after reconstitution. Discard unused material.
Vials of sterile diluent of 0.9% Sodium Chloride Injection, USP, manufactured for Ferring Pharmaceuticals Inc.
FERRING PHARMACEUTICALS INC.
PARSIPPANY, NJ 07054
Read the Patient Information that comes with BRAVELLE® before you start taking it and each time you get a refill, as there may be new information. This leaflet does not take the place of talking to your doctor about your medical condition or your treatment.
BRAVELLE® is a medicine that can help women get pregnant. It is given by injection. You should use BRAVELLE® as your doctor indicates. BRAVELLE® contains a hormone that helps stimulate eggs to grow and mature.
Before using BRAVELLE® you will have a health checkup. This will help your doctor learn more about your medical condition. If your ovaries need help stimulating eggs, your doctor may prescribe BRAVELLE®. You may also be asked to take other medicines. Many women take more than one medicine as part of a pregnancy plan.
Do not use BRAVELLE® if you:
Tell your doctor about any other medicines you are taking. This includes any prescription or nonprescription medicines, vitamins, or herbal supplements.
BRAVELLE® may cause you to have twins or multiple births. Your doctor will talk to you about this.
The most common side effects with BRAVELLE® are headache, vaginal bleeding, nausea, and hot flashes. Sometimes there is a reaction at the spot where you give yourself the injection. This can include bruising, pain, or redness.
These are not all of the side effects of BRAVELLE®. As with any drug, tell your doctor about any side effects or other symptoms you have, or any physical changes.
Note to patients who need multiple vials: Some patients need to take more than 1 vial of BRAVELLE®. If your doctor tells you to do this, prepare the fi rst vial of BRAVELLE® with sterile diluent. (Repeat Step 2.) Then use the liquid in the syringe to mix up to 5 more vials of medicine. Your doctor will tell you how many vials of BRAVELLE® to use.
Medicines are sometimes prescribed for conditions that are not mentioned in Patient Information leaflets. Do not use BRAVELLE® for a condition for which it was not prescribed. Do not give BRAVELLE® to other people, even if they have the same condition you have. It may harm them.
This leaflet summarizes the most important information about BRAVELLE®. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about BRAVELLE® that is written for health professionals.
You can also call 1-888-FERRING.
FERRING PHARMACEUTICALS INC.
PARSIPPANY, NJ 07054
|Marketing Category||Application Number or Monograph Citation||Marketing Start Date||Marketing End Date|
|Labeler - Ferring Pharmaceuticals Inc. (103722955)|
|Ferring GmbH - Kiel||328609615||manufacture|
|F.M. Howell & Company||962888116||pack|
|Jubilant HollisterStier General Partnership||246762764||manufacture|
Revised: 02/2012 Ferring Pharmaceuticals Inc.